Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features.
![Thumbnail](/bitstream/handle/internal/575/JL%20-%20Efficacy%20of%20the%20combination%20of%20ipilimumab%20and%20nivolumab%20following%20progression%20on%20pembrolizumab%20in%20advanced%20melanoma%20with%20poor%20risk%20features.pdf.jpg?sequence=6&isAllowed=y)
View/ Open
Date
2017-04-01ICR Author
Author
Spain, L
Schmid, T
Gore, M
Larkin, J
Type
Journal Article
Metadata
Show full item recordCollections
Subject
Humans
Melanoma
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Ipilimumab
Nivolumab
Research team
Melanoma and Kidney Cancer
Language
eng
Date accepted
2016-12-06
License start date
2017-04
Citation
European journal of cancer (Oxford, England : 1990), 2017, 75 pp. 243 - 244
Publisher
ELSEVIER SCI LTD